The LuMind IDSC Research Consortium is a collaboration of pharmaceutical, therapeutic, and medical device companies working to accelerate Down syndrome research and achieve significant medical and therapeutic outcomes. This is research for the sake of discovery.
The multimillion-dollar project, established in 2021, is the first step in bridging academia, industry, and Down syndrome experts to build a structured and focused translational approach to Down syndrome-related research. The Research Consortium’s shared goal is to create and drive high-impact research projects that identify and develop pre-clinical tools and accelerate research efforts in the DS community.
Industry giants Merck and Company and AbbVie, Inc., are the first members of the LuMind IDSC Research Consortium, an association which is modeled on past collaboration between LuMind IDSC and Eli Lilly and Company.
One of the first programs to receive a boost from the LuMind IDSC Research Consortium is the Longitudinal Investigation for the Enhancement of Down Syndrome Research (LIFE-DSR) study. Support from the Research Consortium enables LuMind IDSC to initiate several sub-studies in the ongoing LIFE-DSR cohort. It will facilitate additional biomarker research that includes a tau PET imaging sub-study, and the expansion of fluid biomarker research to include cerebrospinal fluid and plasma biomarkers. Learn more about this and other key biomarker research here.
